acisoga
metabolitePolyamine metabolite dysregulation marking reduced left-ventricular ejection fraction post-MI.
Pathway placement
Cascade stepOff-pathway / systemic markers
Confidencelow
RationalePolyamine metabolite associated with reduced LV function post-MI.
Druggability
Not assessed (no mapped human gene target).
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum, plasma or urine
Collection tube
Serum separator (gold/red-top, SST) · Lithium heparin (green-top) · Sterile urine container
Method / principle
LC-MS/MS (targeted metabolomics) or enzymatic colorimetric where available
Reagent / substrate
Stable-isotope-labeled internal standard (MS); or enzyme-coupled Trinder reagent
Platform
LC-MS/MS; some automated chemistry
Turnaround · availability
Send-out / research · Specialized / research
Literature evidence(1)
- Non-targeted metabolomics identify polyamine metabolite acisoga as novel biomarker for reduced left ventricular function.ESC heart failure · 2021 · PMID 34811951 · doi